Clck to enlarge and view details
...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
 
US Patents Granted in 2012
US PATENTS IN BLOOD ANTICLOT TECHNOLOGY GRANTED IN 2013
This list includes patents granted in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms included drugs, medications,
formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors, heparin, warfarin and related
technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly relevant documents
Patents Applications in Blood Anticlot Technology, Medications
and Medical Devices Published in 2013

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US GRANTED PATENTS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2013



Patent No.: US8343084B2  Issued: 01/Jan/2013

Title: CLOTTING CASCADE INITIATING APPARATUS AND METHODS OF USE AND METHODS OF CLOSING WOUNDS

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 12/915822   Filing Date: 29/Oct/2010

Abstract:

A wound closure apparatus and associated methods are provided which utilize blood fluid by activating the clotting cascade of blood fluid within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. An apparatus for providing ways of inhibiting anticoagulating agents and slowing fibrin clot degradation are also disclosed. Kits are also disclosed. The invention provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a heparin binding agent which will bind heparin and remove it from the blood fluid.

In further embodiments, the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.

Priority: US2003-389696 Applic. Date: 2003-03-14; US2002-194403 Applic. Date: 2002-07-11; US2000-585488 Applic. Date: 2000-06-01; US2002-291965 Applic. Date: 2002-11-12; US1999-136837P Applic. Date: 1999-06-01

Inventor: NOWAKOWSKI KAROL L [US]; OLSON JAMES E [US]; JOSEPH EDWARD T [US]; ERICSON DANIEL G [US]


Patent No.: US8343485B2  Issued: 01/Jan/2013

Title: Compositions and methods of vascular injury repair

Applicant/Assignee: AMORCYTE, INC

Application No.: 13/312718   Filing Date: 06/Dec/2011

Abstract:

The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.

Priority: US201113295240 Applic. Date: 2011-11-14; US2009-401291 Applic. Date: 2009-03-10; US2006-552396 Applic. Date: 2006-10-24; US2005-734151P Applic. Date: 2005-11-07

Inventor: PECORA ANDREW L [US]; PRETI ROBERT A [US]


Patent No.: US8343526B2  Issued: 01/Jan/2013

Title: Methods and apparatuses for conducting assays

Applicant/Assignee: MESO SCALE TECHNOLOGIES, LLC

Application No.: 13/275398   Filing Date: 18/Oct/2011

Abstract:

Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Priority: US2010-831139 Applic. Date: 2010-07-06; US2005-145528 Applic. Date: 2005-06-03; US2004-576710P Applic. Date: 2004-06-03

Inventor: BILLADEAU MARK A [US]; DEBAD JEFF D [US]; GLEZER ELI N [US]; LELAND JONATHAN K [US]; WIJAYAWARDHANA CHARLES A [DE]


Patent No.: US8343730B2  Issued: 01/Jan/2013

Title: Method for determining the course of proteolytic activity

Applicant/Assignee: THROMBINOSCOPE B.V

Application No.: 12/513205   Filing Date: 02/Nov/2007

Abstract:

A method is provided for determining in real time the course of proteolytic, e.g., thrombin activity, in a sample of clotting blood or plasma. By frequent mixing of a sample, clot formation may be controlled in a dense manner such that the majority of the sample remains fluid. This will inhibit cell precipitation and allow for informative monitoring as signal substrate is added.

Priority: EP20060022813 Applic. Date: 2006-11-02; WO2007EP09528 Applic. Date: 2007-11-02

Inventor: GIESEN PETER L A [NL]; TAPPENDEN KERRY [GB]; JONES WYNNE [GB]


Patent No.: US8343995B2  Issued: 01/Jan/2013

Title: Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use

Applicant/Assignee: CYDEX PHARMACEUTICALS, INC

Application No.: 12/597908   Filing Date: 26/Apr/2008

Abstract:

The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution.

The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.

Priority: US2007-914555P Applic. Date: 2007-04-27; WO2008US61697 Applic. Date: 2008-04-26

Inventor: MOSHER GEROLD L [US]; WEDEL REBECCA L [US]; JOHNSON KAREN T [US]; MACHATHA STEPHEN G [US]; COWEE JANE A [US]; CUSHING DANIEL J [US]


Patent No.: US8348844B2  Issued: 08/Jan/2013

Title: Automated Blood Sampler and Analyzer

Applicant/Assignee:

Application No.: 12/326857   Filing Date: 02/Dec/2008

Abstract:

An automated blood sampler integratable with a glucose monitor comprises a catheter connected to a tube-set forming a single blood passageway

a clamp-on air-bubble sensor and a occlusion sensor externally attached to the tube set

a single peristaltic pump and two 3-way pinch valves attached to the tube set and control fluid flow. The sampler draws blood from a stationary patient, samples the blood for analytical measurement of blood parameters

after which the passageway is rinsed, the blood re-infused, and slow saline infusion prevents vein collapse. The cycle repeats at user or predefined intervals. In another preferred embodiment, blood is not re-infused, and only one 3-way pinch valve is used.

Priority:

Inventor: KUNJAN KISLAYA [US]; LLOYD JR FRANK PERRY [US]


Patent No.: US8349189B2  Issued: 08/Jan/2013

Title: METHOD FOR THE PREPARATION OF AT LEAST ONE COMPOUND FROM BLOOD, AND EXTRACTION DEVICE FOR USE IN THE EXECUTION OF SAID METHOD

Applicant/Assignee: BIOTECHNOLOGY INSTITUTE, I MAS D, S.L,, BIOTECHNOLOGY INSTITUTE, I MAS D, S.L

Application No.: 12/780287   Filing Date: 14/May/2010

Abstract:

Method for the preparation of at least one compound with biological properties from blood, where said method is performed in sealed tubes at a pressure below atmospheric pressure, thereby reducing or preventing the bacterial contamination of the compound through handling. The method comprises the repetition, for as many times as is required, of the following steps: connecting a second container that is vacuum-sealed to an extraction device connected in turn to a first container that contains blood separated into fractions, waiting for a period of time until the required fraction(s) is/are transferred, and removing said second container, with it thus being possible to obtain several second containers with different compounds for different medical applications including biological therapies.

The steps may be performed in a closed system, without removing the caps of the containers, or alternatively the first container may be opened prior to the introduction of the extraction device.

Priority: ES20090001227 Applic. Date: 2009-05-14; ES20100000306 Applic. Date: 2010-03-10

Inventor: ANITUA ALDECOA EDUARDO [ES]


Patent No.: US8349254B2  Issued: 08/Jan/2013

Title: Circuit For Collecting Blood Component And Apparatus For Collecting Blood Component

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 11/988105   Filing Date: 04/Jul/2006

Abstract:

A circuit for collecting a blood component includes a blood collection device provided with a blood collection needle through which blood is collected from a blood donor, a blood separator in which the blood collected by the above blood collection device is separated, a blood component collection bag in which a predetermined blood component separated by the above blood separator is collected, a blood line in which the blood collection needle is connected to an inlet of the blood separator, a line for removing an initial blood flow, which branches from a first branching portion formed in the blood line, and in which an initial flow of blood collected from the blood donor is removed, and an anticoagulant-injection line that branches from a second branching portion, formed in the line for removing the initial blood flow, and into which an anticoagulant is injected.

Priority: JP20050200623 Applic. Date: 2005-07-08; WO2006JP313328 Applic. Date: 2006-07-04

Inventor: HOSHINO YOSHITERU [JP]; YOKOO YOSHIHIRO [JP]; YAMAZAKI YUUSUKE [JP]


Patent No.: US8352011B2  Issued: 08/Jan/2013

Title: BLOOD CONTACTING SENSOR

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 12/264810   Filing Date: 04/Nov/2008

Abstract:

The invention provides methods and apparatus for detecting an analyte in blood. The apparatus is particularly suited for bringing a sensor into direct contact with blood in vivo. The apparatus comprises a sensor that detects the presence of an analyte and an assembly means. The assembly means has a sensor end, wherein the sensor end of the assembly means is affixed to the sensor, and the assembly means is adapted for coupling with a venous flow device. By coupling with a venous flow device, the assembly means brings the sensor into direct contact with blood flowing through the venous flow device. Examples of venous flow devices that bring the sensor into direct contact with the blood of a subject include, but are not limited to, intravenous catheters and external blood loops, such as are used in extra corporeal membrane oxygenation or hemodialysis.

Priority: US2004-935954 Applic. Date: 2004-09-08

Inventor: VAN ANTWERP NANNETTE M [US]; ENEGREN BRADLEY J [US]; MASTROTOTARO JOHN J [US]; SHAH RAJIV [US]; HOSS UDO [US]; ZHANG YANAN [US]; WANG JENN-HANN LARRY [US]; CLARK KENT L [US]


Patent No.: US8357539B2  Issued: 22/Jan/2013

Title: ACTIVATED PARTIAL THROMBOPLASTIN TIME MEASURING REAGENT, ACTIVATED PARTIAL THROMBOPLASTIN TIME MEASURING METHOD, AND DETERMINATION METHOD FOR DETERMINING PRESENCE OR ABSENCE OF BLOOD COAGULATION INHIBITOR

Applicant/Assignee: SYSMEX CORPORATION

Application No.: 12/976681   Filing Date: 22/Dec/2010

Abstract:

An activated partial thromboplastin time measuring reagent, including a first reagent containing a phospholipid and an activator and a second reagent containing a herparin neutralizer and a calcium salt is disclosed. An activated partial thromboplastin time measuring method, and a determination method for determining a presence or absence of a blood coagulation inhibitor are also disclosed.

Priority: JP20090294107 Applic. Date: 2009-12-25

Inventor: YOSHIDA KAZUYO [JP]; OKUDA MASAHIRO [JP]


Patent No.: US8360977B2  Issued: 29/Jan/2013

Title: CONTINUITY CIRCUITS FOR DETECTING ACCESS DISCONNECTION

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 11/862984   Filing Date: 27/Sep/2007

Abstract:

A monitor for an extracorporeal therapy access site is disclosed. The monitor includes a bandage atop or adjacent the access site and a sensor for monitoring the bandage. The bandage includes a layer of polymer that expands when wetted with blood. The expansion causes a break in continuity of the sensor, or in an alternate embodiment, causes a sensor to cease detecting a target. When the break occurs, the control circuit monitoring the bandage sends a signal that a break has occurred, and a remote monitor then takes appropriate action, such as ceasing therapy, sending an alert, or sounding an alarm. In another embodiment, connecting wires in a continuity circuit are held apart by a polymer that dissolves when contacted by blood. If a leak occurs and a small portion of the polymer dissolves, the wires make contact, thus detecting a blood leak.

Priority:

Inventor: MARTTILA ALAN W [US]; CHAN WILLIAM W [US]; BHAGTANI REEMA A [US]


Patent No.: US8361022B2  Issued: 29/Jan/2013

Title: Apparatus for transdermal delivery of parathyroid hormone agents

Applicant/Assignee: ALZA CORPORATION

Application No.: 12/459499   Filing Date: 01/Jul/2009

Abstract:

An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.

Priority: US2005-084634 Applic. Date: 2005-03-18; US2004-571304P Applic. Date: 2004-05-13; US2004-585276P Applic. Date: 2004-07-01; US2005-643660P Applic. Date: 2005-01-12

Inventor: AMERI MAHMOUD [US]; CORMIER MICHEL J N [US]; MAA YUH-FUN [US]; DADDONA PETER E [US]; KAMBERL MARIKA [US]


Patent No.: US8361037B2  Issued: 29/Jan/2013

Title: Microneedles, microneedle arrays, and systems and methods relating to same

Applicant/Assignee: VALERITAS, INC

Application No.: 10/251480   Filing Date: 19/Sep/2002

Abstract:

The microneedle devices disclosed herein in some embodiments include a substrate

one or more microneedles

and, optionally, a reservoir for delivery of drugs or collection of analyte, as well as pump(s), sensor(s), and/or microprocessor(s) to control the interaction of the foregoing.

Priority: US2001-323417P Applic. Date: 2001-09-19

Inventor: GONNELLI ROBERT R [US]


Patent No.: US8366696B2  Issued: 05/Feb/2013

Title: ABSORBENT ARTICLE

Applicant/Assignee: DAIO PAPER CORPORATION

Application No.: 12/448658   Filing Date: 27/Dec/2007

Abstract:

An absorbent article comprises an absorbent interposed between a liquid-permeable surface sheet and a back sheet. The absorbent is constituted of a set of left and right absorbent elements arranged substantially along the longitudinal direction of the absorbent article. The absorbent element of one side is formed as a dogleg to the right in a top plan view whereas the absorbent element of the other side is formed as a dogleg to the left in a top plan view, so that the absorbent elements have an intersecting portion intersecting in at least the region containing the portion corresponding to the blood discharge opening of the wearer.

Priority: JP20060351165 Applic. Date: 2006-12-27; WO2007JP75109 Applic. Date: 2007-12-27

Inventor: KONAWA SATOKO [JP]


Patent No.: US8367148B2  Issued: 05/Feb/2013

Title: Methods of Making Biocomposite Medical Constructs and Related Constructs Including Artificial Tissues, Vessels and Patches

Applicant/Assignee: MIMEDX GROUP, INC

Application No.: 12/576423   Filing Date: 09/Oct/2009

Abstract:

Methods for making collagen based biocomposite constructs and related devices include: (a) winding at least one collagen fiber a number of revolutions about a length of a support member having a long axis, the winding having at least one defined pitch and/or fiber angle relative to the long axis of the support member to form an elongate construct

and (b) applying a fluid polymeric material, such as, for example, an acrylate emulsion and/or other thermoplastic material, onto the collagen fiber during the winding step. Optionally, the fluid polymeric material can include antibiotics and/or other therapeutic agents for additional function/utility.

Priority: US2008-103995P Applic. Date: 2008-10-09; US2008-138165P Applic. Date: 2008-12-17

Inventor: GREENHALGH KERRIANN [US]; LI MENGYAN [US]; KOOB THOMAS J [US]


Patent No.: US8372025B2  Issued: 12/Feb/2013

Title: Automation and optimization of CRRT treatment using regional citrate anticoagulation

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 11/525800   Filing Date: 21/Sep/2006

Abstract:

A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Priority: US2005-719718P Applic. Date: 2005-09-22

Inventor: LANNOY JEAN-MICHEL [FR]


Patent No.: US8372343B2  Issued: 12/Feb/2013

Title: MULTIPLE COAGULATION TEST CARTRIDGE AND METHOD OF USING SAME

Applicant/Assignee:

Application No.: 11/952914   Filing Date: 07/Dec/2007

Abstract:

Embodiments of the present invention relate to multiple coagulation test cartridges and methods of using such cartridges. In one embodiment the cartridge is a disposable single-use cartridge for use in evaluating blood clotting. The cartridge includes multiple containers, such as tubes, each of which includes one or more coagulation affecting substances. The containers can be pre-filled with substances in amounts suitable for use with a single patient's blood sample. The cartridge may include one or more containers, each of which has multiple sections, or volumes, each section storing a different coagulation affecting substance. In another embodiment the cartridge is used in a method for determining at least one appropriate coagulation affecting substance for modifying a patient's coagulation status using a multiple coagulation test system.

Priority:

Inventor: GOLDSTEIN SHELDON [US]


Patent No.: US8377395B2  Issued: 19/Feb/2013

Title: Integrated Blood Specimen Processor

Applicant/Assignee:

Application No.: 13/097975   Filing Date: 29/Apr/2011

Abstract:

A blood specimen processor by means of which blood specimens are collected into a collection tube containing an anticoagulant and a molded buoy of predetermined density between 1.045 and 1.084 with an embedded water swellable o-ring that expands to form a robust seal in a leucocyte density gradient between the buoy's outer surface and tube's inner surface. The buoy is made of a first resin and a second resin, the first resin having a lower density than the second resin, the first resin and the second resin being present in such amounts and relative proportions so that the body has an overall density between 1.045 and 1.084 and preferably, a center of gravity below a geometric center of the body. When the blood specimen contained in the processor is centrifuged, the buoy is thrust through the separating blood and the developing interface of erythrocytes, leucocytes, and plasma.

A reproducible gradient develops that builds a reproducible buffy coat ring around the upper trough at the junction of the edge of the separator buoy and the tube wall. The relative proportions of resin are controlled to create a separator buoy of a desired density so that after centrifugation the buffy coat or other cells of interest will be above or below the water swellable o-ring.

Priority: US2010-329339P Applic. Date: 2010-04-29

Inventor: COLEMAN CHARLES M [US]


Patent No.: US8377669B2  Issued: 19/Feb/2013

Title: REDUCING LEUKOCYTE INTERFERENCE IN NON-COMPETITIVE IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/620179   Filing Date: 17/Nov/2009

Abstract:

The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads

and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; MOSS ADAM ROGER [CA]; DAVIS GRAHAM [US]


Patent No.: US8380539B2  Issued: 19/Feb/2013

Title: PERSONALIZED MEDICINE MANAGEMENT SOFTWARE

Applicant/Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC

Application No.: 12/300104   Filing Date: 08/May/2007

Abstract:

The invention provides personalized medicine management software for determining a series of recommended doses of a medication for a patient. The software contains code to receive information regarding a combination of at least one genetic factor and personal attributes for the patient that are predictive of the patient's reaction to a series of doses of the medication. Using a predictive mathematical model specific to the medication, the code calculates the series of recommended doses specific to the patient's genetic factor and personal attributes and specific to the medication. The series of recommended doses is outputted. In preferred embodiments, the output is the form of an interactive display. The interactive display permits a user, typically a health care professional, to input actual doses and actual patient responses.

The subsequent series of recommended doses is preferably then adjusted, in real time, to account for the actual doses and actual patient responses.

Priority: US2006-798855P Applic. Date: 2006-05-09; US2006-859803P Applic. Date: 2006-11-17; WO2007US11033 Applic. Date: 2007-05-08

Inventor: LINDER MARK W [US]; VALDES JR ROLAND [US]


Patent No.: US8383403B2  Issued: 26/Feb/2013

Title: RETICULOCYTE MIMETICS AND METHOD OF PREPARATION OF THE SAME

Applicant/Assignee: SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD

Application No.: 12/774442   Filing Date: 05/May/2010

Abstract:

In one aspect of the present disclosure there is provided a method for preparing reticulocyte mimetics. In another aspect of the present disclosure there are provided reticulocyte mimetics obtained using the method. In yet another aspect of the present disclosure there is provided a whole blood reference control including the reticulocyte mimetics as provided. In still another aspect of the present disclosure there is provided a composition useful for preparing reticulocyte mimetics.

Priority: CN20091107227 Applic. Date: 2009-05-06

Inventor: WANG LU [CN]; XU ZUYUE [CN]; XIA TAO [CN]


Patent No.: US8386053B2  Issued: 26/Feb/2013

Title: SUBCLAVIAN ANSAE STIMULATION

Applicant/Assignee: MEDTRONIC, INC

Application No.: 12/262867   Filing Date: 31/Oct/2008

Abstract:

Techniques for improving cardiac performance by applying stimulation to the subclavian ansae nerve of a patient are disclosed. In one example, a method comprises identifying a human patient as having a cardiac condition, and delivering stimulation therapy to a subclavian ansae nerve of a human patient with a stimulation electrode.

Priority:

Inventor: KORNET LILIAN [NL]


Patent No.: US8389293B2  Issued: 05/Mar/2013

Title: REDUCING LEUKOCYTE INTERFERENCE IN COMPETITIVE IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/620230   Filing Date: 17/Nov/2009

Abstract:

The invention is directed to methods and devices for reducing interference from leukocytes in competitive analyte immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads opsonized for leukocytes

and (b) performing a competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]


Patent No.: USRE44050E1  Issued: 05/Mar/2013

Title: Vascular prosthesis

Applicant/Assignee: UNIVERSITY OF SOUTH FLORIDA

Application No.: 12/777789   Filing Date: 02/Jun/2006

Abstract:

The subject invention concerns vascular prosthetic devices and methods for ascending aorta and/or valve replacement in humans and animals. In one embodiment, a device of the invention includes a vessel-like structure having a first end adapted for surgical attachment to a left ventricle, a second end adapted for surgical attachment to an aorta, and, interposed between the first and second ends, a sinus portion configured in the shape of the sinuses of Valsalva in a human aortic valve.

Priority: US2004-561929 Applic. Date: 2004-06-28; US2003-483035P Applic. Date: 2003-06-27; WO2004US21046 Applic. Date: 2004-06-28

Inventor: KNIGHT JOSEPH A [US]; STROM JOEL A [US]; VAN AUKER MICHAEL D [US]; ONDROVIC LEO E [US]; MUFFLY KARL [US]; MCMILLAN DONALD E [US]


Patent No.: US8394046B2  Issued: 12/Mar/2013

Title: METHOD AND DEVICE FOR CHECKING THE CORRECT COUPLING OF A SUPPLY DEVICE TO A THERAPY DEVICE

Applicant/Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Application No.: 12/451565   Filing Date: 13/May/2008

Abstract:

A method provides for checking the correct coupling of an adding device to a therapeutic appliance that includes an extracorporeal circuit with which the adding device is connected such that a drug can be introduced into the extracorporeal circuit by the adding device during operation of the therapeutic appliance. The adding device is coupled to the extracorporeal circuit on the suction side of a pump disposed in the extracorporeal circuit, with a portion in the region of negative pressure of the extracorporeal circuit being in connection with a portion of the adding device that is closed with respect to the other parts of the extracorporeal circuit, and with the pressure in the closed portion being varied and measured.

Priority: DE20071024463 Applic. Date: 2007-05-25; WO2008EP03835 Applic. Date: 2008-05-13

Inventor: NUERNBERGER THOMAS [DE]; BLASEK MARCO [DE]; KLOEFFEL PETER [DE]


Patent No.: US8394325B2  Issued: 12/Mar/2013

Title: MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/815132   Filing Date: 14/Jun/2010

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]


Patent No.: US8400298B2  Issued: 19/Mar/2013

Title: DEVICE FOR THE TREATMENT AND EXTRACORPOREAL CIRCULATION OF BLOOD OR BLOOD COMPONENTS

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 12/809032   Filing Date: 04/Aug/2008

Abstract:

The invention relates to a medical device for providing a plurality of extracorporeal blood or plasma treatments, apt to receive at least one disposable article that can be connected to extracorporeal circuit, each disposable article being equipped with storage means containing information about the disposable article, the device comprising a first receiving station (2) for disposable articles (100) with a first reading means (3) for the associated article, a second receiving station (3) for disposable articles (100) with a second reading means (3) for the associated article, a memory comprising information concerning at least one treatment protocol designed to be executed by the device, and information concerning a configuration of the disposable articles necessary for each treatment protocol at each receiving station, a control unit (10)

for comparing the stored configuration of articles concerning a treatment protocol with the configuration of articles once it is installed.

Priority: FR20070008917 Applic. Date: 2007-12-20; WO2008IB02033 Applic. Date: 2008-08-04

Inventor: RADA HIRAM [FR]


Patent No.: US8409167B2  Issued: 02/Apr/2013

Title: DEVICES FOR DELIVERING SUBSTANCES THROUGH AN EXTRA-ANATOMIC OPENING CREATED IN AN AIRWAY

Applicant/Assignee: BRONCUS TECHNOLOGIES, INC, BRONCUS MEDICAL INC

Application No.: 11/538950   Filing Date: 05/Oct/2006

Abstract:

Devices and methods for delivering substances to lung tissue through an extra-anatomic passage created in an airway.

Priority: US2004-895022 Applic. Date: 2004-07-19

Inventor: ROSCHAK EDMUND J [US]


Patent No.: US8425448B2  Issued: 23/Apr/2013

Title: ADJUSTING PH IN A METHOD OF SEPARATING WHOLE BLOOD

Applicant/Assignee: GAMBRO BCT, INC, TERUMO BCT, INC

Application No.: 11/668715   Filing Date: 30/Jan/2007

Abstract:

This invention is directed to a method of collecting and separating whole blood into components. The method includes the steps of adding an anticoagulant having an acidic pH to a bag for collecting and/or separating whole blood, collecting whole blood in the bag, loading the bag containing anticoagulated whole blood on a rotor, spinning the bag on the rotor to separate the whole blood into at least one component

and squeezing the bag on the rotor to push the component from the separation bag into at least one satellite bag.

Priority: US2006-766586P Applic. Date: 2006-01-30

Inventor: FELT THOMAS [US]; PIHLSTEDT PETER [SE]; GIBBS BRUCE [US]


Patent No.: US8425899B2  Issued: 23/Apr/2013

Title: COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY

Applicant/Assignee:

Application No.: 13/285606   Filing Date: 31/Oct/2011

Abstract:

The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.

Priority: US2010-910328 Applic. Date: 2010-10-22; US2006-552396 Applic. Date: 2006-10-24; US2009-401291 Applic. Date: 2009-03-10; US2009-629361 Applic. Date: 2009-12-02; US2009-254539P Applic. Date: 2009-10-23; US2005-734151P Applic. Date: 2005-11-07; US2008-119552P Applic. Date: 2008-12-03; US2009-169850P Applic. Date: 2009-04-16

Inventor: PECORA ANDREW L [US]; PRETI ROBERT A [US]


Patent No.: US8430861B2  Issued: 30/Apr/2013

Title: MICROVASCULAR OBSTRUCTION DETECTION AND THERAPY

Applicant/Assignee: OSPREY MEDICAL, INC

Application No.: 12/376086   Filing Date: 01/Aug/2007

Abstract:

A method of detecting and treating a microvascular obstruction is provided. In one embodiment, a catheter is provided for both detecting the microvascular obstruction and treating or removing the obstruction.

Priority: US2006-821216P Applic. Date: 2006-08-02; US2006-821678P Applic. Date: 2006-08-07; US2006-864130P Applic. Date: 2006-11-02; US2006-864336P Applic. Date: 2006-11-03; WO2007US75002 Applic. Date: 2007-08-01

Inventor: SCHWARTZ ROBERT S [US]; VAN TASSEL ROBERT A [US]


Patent No.: US8435792B2  Issued: 07/May/2013

Title: Methods and Compositions for Treating Bleeding Disorders

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 13/111684   Filing Date: 19/May/2011

Abstract:

Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

Priority: US201113006396 Applic. Date: 2011-01-13; US2010-335964P Applic. Date: 2010-01-14

Inventor: DOCKAL MICHAEL [AT]; EHRLICH HARTMUT [AT]; SCHEIFLINGER FRIEDRICH [AT]


Patent No.: US8445225B2  Issued: 21/May/2013

Title: METHODS FOR THE DETECTION OF CIRCULATING TUMOR CELLS

Applicant/Assignee: THE SCRIPPS RESEARCH INSTITUTE

Application No.: 12/553733   Filing Date: 03/Sep/2009

Abstract:

The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers.

Priority: US2008-094819P Applic. Date: 2008-09-05

Inventor: KUHN PETER [US]; GRIFFIN JOHN HO [US]; BETHEL KELLY [US]; MARRINUCCI DENA [US]


Patent No.: US8445287B2  Issued: 21/May/2013

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee: WADA, INC

Application No.: 12/932822   Filing Date: 07/Mar/2011

Abstract:

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents.

One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

Priority: US2009-378456 Applic. Date: 2009-02-14

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Patent No.: US8449488B2  Issued: 28/May/2013

Title: BLOOD COMPONENT COLLECTION APPARATUS AND METHOD

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 12/488649   Filing Date: 22/Jun/2009

Abstract:

A blood component collection apparatus comprises a blood component collecting circuit which includes an anticoagulant line for feeding an anticoagulant and a line for collecting an initial flow of collected blood. In the blood component collection apparatus, air is intermediately present between the anticoagulant and the blood in the passage of a blood collection needle side line, after a priming operation is performed in which anticoagulant is supplied from the anticoagulant line toward the side of a centrifugal separator in the blood collection needle side line through a branch connector and after an initial flow collecting operation is performed in which the initial flow of blood is collected.

Priority: JP20050178316 Applic. Date: 2005-06-17; US2006-453840 Applic. Date: 2006-06-16

Inventor: HIRABUKI MAKOTO [JP]


Patent No.: US8449490B2  Issued: 28/May/2013

Title: Disc shunt delivery with stepped needle

Applicant/Assignee: ALEEVA MEDICAL INC

Application No.: 13/199906   Filing Date: 12/Sep/2011

Abstract:

A solid stepped needle delivers a disc shunt bridging between muscle and a degenerated disc, drawing blood plasma from muscle into the degenerated disc to alleviate back pain and regenerate the disc. The device further includes pull lines attached to the ends of the disc shunt for withdrawing and repositioning the stepped needle during shunt delivery.

Priority: US2010-403188P Applic. Date: 2010-09-11

Inventor: YEUNG JEFFREY [US]; YEUNG TERESA [US]; YEUNG ANDREW [US]


Patent No.: US8454548B2  Issued: 04/Jun/2013

Title: System and Method for Plasma Reduced Platelet Collection

Applicant/Assignee: HAEMONETICS CORPORATION

Application No.: 12/102486   Filing Date: 14/Apr/2008

Abstract:

A method and apparatus for collecting plasma reduced platelets potentially suspended in a synthetic solution from a donor. Whole blood is drawn from the donor and introduced into a separation chamber. Platelets are extracted from the separation chamber into a container, using, for example, surge (with anticoagulated plasma or a synthetic solution) or push methodologies. The remaining blood components in the separation chamber are returned back to the donor. The steps of drawing whole blood and introducing the whole blood into the separation chamber, extracting platelets from the separation chamber into the container, and returning the remaining components in the chamber back to the donor are repeated. The sequestered platelets in the container are reintroduced into the separation chamber, whereupon a plasma reduced platelet product is extracted.

Priority:

Inventor: OHASHI TOSHIYASU [JP]; PAGES ETIENNE [FR]; UHLMANN DOMINIQUE [US]; MAILLARD PASCAL [CH]; RAGUSA MICHAEL [US]


Patent No.: US8455440B2  Issued: 04/Jun/2013

Title: Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 13/213912   Filing Date: 19/Aug/2011

Abstract:

The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Priority: US2008-101644 Applic. Date: 2008-04-11; US2007-911852P Applic. Date: 2007-04-13

Inventor: SINHA UMA [US]; HOLLENBACH STANLEY J [US]; ANDRE PATRICK [US]


Patent No.: US8466280B2  Issued: 18/Jun/2013

Title: CO-CRYSTAL COMPOUND OF RIVAROXABAN AND MALONIC ACID

Applicant/Assignee: BAYER SCHERING PHARMA AG, BAYER INTELLECTUAL PROPERTY GMBH

Application No.: 12/997474   Filing Date: 03/Jun/2009

Abstract:

The present invention relates to a novel cocrystal compound of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban) and malonic acid, to processes for its preparation, to medicaments comprising this compound and to their use for controlling diseases.

Priority: DE20081028071 Applic. Date: 2008-06-12; WO2009EP03952 Applic. Date: 2009-06-03

Inventor: GRUNENBERG ALFONS [DE]; FAEHNRICH KARSTEN [DE]; QUECKENBERG OLAF [DE]; REUTE CHRISTIANE [DE]; KEIL BIRGIT [DE]; GUSHURST KAREN SUE [US]; STILL EZRA JOHN [US]


Patent No.: US8469873B2  Issued: 25/Jun/2013

Title: BLOOD VESSEL WRAP

Applicant/Assignee: SUNSHINE HEART COMPANY PTY LTD

Application No.: 12/962327   Filing Date: 07/Dec/2010

Abstract:

A wrap (20) for securing about a blood vessel (36) by encasing a section of the vessel. The wrap (20) being of thin flexible construction having two ends (22, 24) and two sides (26, 28). The wrap (20) is more elastic or stretchable at, near, or along at least some of its sides (22, 24) compared to at, near, or along its centre, to provide strain relief from wrapped to unwrapped aorta. The wrap (20) is not inelastic, so that loss of aortic compliance is minimised or enhanced. The wrap (20) is adapted to apply, in use, less compressive force at, near, or along at least some of its sides (22, 24) compared to at, near, or along its centre.

Priority: AU20030905992 Applic. Date: 2003-10-30; US2007-595602 Applic. Date: 2007-02-22; WO2004AU01484 Applic. Date: 2004-10-28

Inventor: MILLER SCOTT H [AU]; PETERS WILLIAM SUTTLE [NZ]; DE PLATER GEMMA [AU]


Patent No.: US8470241B2  Issued: 25/Jun/2013

Title: FLUID INJECTION AND SAFETY SYSTEM

Applicant/Assignee: OPTISCAN BIOMEDICAL CORPORATION

Application No.: 12/123422   Filing Date: 19/May/2008

Abstract:

Various medical systems and methods are described, including a medical monitoring system. The medical monitoring system can have a fluid system configured to receive bodily fluid and optically analyze said fluid to determine analyte concentration. The fluid system can have a removable portion. The removable portion can have an opening with a port. The system can also have a container configured to contain anticoagulant. The container can have a portion configured to mate with the port of the removable portion. The container can be further configured to not fit into a conventional luer fitting. An anti-coagulant insertion apparatus is also described. The apparatus can have a syringe, a dock with a port, and an adapter configured to connect the syringe to the port. The dock can also have a tab configured to move with the port.

Priority: US2007-939023P Applic. Date: 2007-05-18; US2007-979374P Applic. Date: 2007-10-11

Inventor: RIVAS GIL [US]; BUTLER MICHAEL [US]; CHIOU JEFFREY T [US]; LIM EUGENE [US]


Patent No.: US8476079B2  Issued: 02/Jul/2013

Title: REAGENTS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/771634   Filing Date: 30/Apr/2010

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.

Priority:

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]; OMAKOR JOHN EMEGBERO [CA]; MOSS ADAM ROGER [CA]; GUHADOS GANESH [CA]


Patent No.: US8481081B2  Issued: 09/Jul/2013

Title: Pharmaceutical solid dispersions

Applicant/Assignee: PFIZER INC, BEND RESEARCH, INC

Application No.: 10/459808   Filing Date: 10/Jun/2003

Abstract:

A composition comprises a solid dispersion comprising a low-solubility drug and at least one polymer. At least a major portion of the drug in the dispersion is amorphous. The polymer has a glass transition temperature of at least 100 DEG C. measured at a relative humidity of fifty percent. Another aspect of the invention comprises the same composition except that the dispersion has a glass transition temperature of at least 50 DEG C. at a relative humidity of fifty percent. In another aspect of the invention, a composition comprises a solid dispersion comprising a low-solubility drug and a stabilizing polymer. At least a major portion of the drug in the dispersion is amorphous. The composition also includes a concentration-enhancing polymer that increases the concentration of the drug in a use environment.

The stabilizing polymer has a glass transition temperature that is greater than the glass transition temperature of the concentration-enhancing polymer at a relative humidity of 50%.

Priority: US2000-495049 Applic. Date: 2000-01-31; US1999-119401P Applic. Date: 1999-02-10

Inventor: BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; SHANKER RAVI M [US]


Patent No.: US8481512B2  Issued: 09/Jul/2013

Title: COMPOSITIONS AND METHODS FOR MODULATION OF VASCULAR STRUCTURE AND/OR FUNCTION

Applicant/Assignee: MARINE POLYMER TECHNOLOGIES, INC.,, MARINE POLYMER TECHNOLOGIES, INC

Application No.: 12/816957   Filing Date: 16/Jun/2010

Abstract:

The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.

Priority: US2009-482986 Applic. Date: 2009-06-11; US2006-542983 Applic. Date: 2006-10-03; US2002-194740 Applic. Date: 2002-07-12; US2001-781182 Applic. Date: 2001-02-12

Inventor: VOURNAKIS JOHN N [US]; FINKIELSZTEIN SERGIO [US]


Patent No.: US8486721B2  Issued: 16/Jul/2013

Title: MAGNETIC BEADS FOR REDUCING LEUKOCYTE INTERFERENCE IN IMMUNOASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 13/559753   Filing Date: 27/Jul/2012

Abstract:

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.

Priority: US2010-815132 Applic. Date: 2010-06-14

Inventor: CAMPBELL JOHN LEWIS EMERSON [CA]; DAVIS GRAHAM [US]


Patent No.: US8500712B2  Issued: 06/Aug/2013

Title: KIT FOR COLLECTING BLOOD, PREFERABLY PERIPHERAL BLOOD, FOR THE PRODUCTION OF STEM CELLS

Applicant/Assignee: SALES ENGINEERING AG, THANKSTEM SRL

Application No.: 12/922498   Filing Date: 17/Mar/2009

Abstract:

A kit for collecting blood, preferably peripheral blood, for the production of pluripotent stem cells comprises at least a first container, able to contain the blood taken, which contains an anticoagulant and the substance MCSF (Macrophage Colony Stimulating Factor).

Priority: IT2008UD00058 Applic. Date: 2008-03-18; WO2009EP53144 Applic. Date: 2009-03-17

Inventor: POLETTINI MARCO [IT]; GAMBACURTA ALESSANDRA [IT]


Patent No.: US8501231B2  Issued: 06/Aug/2013

Title: PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 13/527536   Filing Date: 19/Jun/2012

Abstract:

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Priority: US201113208305 Applic. Date: 2011-08-11; US2000-742785 Applic. Date: 2000-12-20; US1999-171841P Applic. Date: 1999-12-23

Inventor: CURATOLO WILLIAM J [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; LORENZ DOUGLAS A [US]


Patent No.: US8506825B2  Issued: 13/Aug/2013

Title: Method and apparatus for controlling the flow rate of washing solution during the washing step in a blood centrifugation bowl

Applicant/Assignee: SORIN GROUP ITALIA S.R.L

Application No.: 11/604664   Filing Date: 27/Nov/2006

Abstract:

A method of washing blood mixed with undesirable elements not normally found in healthy whole blood to remove the undesirable elements, the method comprising: separating the blood into components according to relative densities of the components with a rotating centrifuge bowl

providing a port through which fluid exits the bowl, the exiting fluid having a concentration of undesirable elements

flowing washing solution into the centrifuge bowl at an initial flow rate

monitoring the fluid exiting the bowl with an optical sensor having an output signal indicative of the composition of the exiting fluid

and increasing and decreasing the flow rate of the wash solution as a function of the output signal.

Priority:

Inventor: FORTINI MATTEO [IT]; REGGIANI STEFANO [IT]; PANZANI IVO [IT]


Patent No.: US8512178B2  Issued: 20/Aug/2013

Title: Slingblade Broad-head Delivery System

Applicant/Assignee:

Application No.: 13/167619   Filing Date: 23/Jun/2011

Abstract:

A bow hunting broad-head system having a mechanical cutter which opens after impact. The broad-head flies to its destination with minimal drag and having good balance. After impact, the tip opens to a larger diameter creating a devastating wound and releases the payload inside the animal.

Priority:

Inventor: PEETZ JASON L [US]; SCHROEDER MARK F [US]


Patent No.: US8512754B2  Issued: 20/Aug/2013

Title: Stabilized products, processes and devices for preparing the same

Applicant/Assignee:

Application No.: 13/199573   Filing Date: 02/Sep/2011

Abstract:

A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.

Priority: US2007-796451 Applic. Date: 2007-04-27; US2004-007104 Applic. Date: 2004-12-08; US2003-527810P Applic. Date: 2003-12-08; US2004-619863P Applic. Date: 2004-10-18

Inventor: NEEDHAM DAVID [US]


Patent No.: US8529486B2  Issued: 10/Sep/2013

Title: CITRATE ANTICOAGULATION SYSTEM FOR EXTRACORPOREAL BLOOD TREATMENTS

Applicant/Assignee: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC

Application No.: 13/359109   Filing Date: 26/Jan/2012

Abstract:

A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2006-602827 Applic. Date: 2006-11-21; US2003-742137 Applic. Date: 2003-12-19; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20; US2005-739086P Applic. Date: 2005-11-22

Inventor: LANNOY JEAN-MICHEL [FR]


Patent No.: US8529939B2  Issued: 10/Sep/2013

Title: Mucoadhesive drug delivery devices and methods of making and using thereof

Applicant/Assignee: GEL-DEL TECHNOLOGIES, INC

Application No.: 11/007053   Filing Date: 08/Dec/2004

Abstract:

The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.

Priority: US2003-527962P Applic. Date: 2003-12-08

Inventor: MASTERS DAVID B [US]; BERG ERIC P [US]


Patent No.: US8530455B2  Issued: 10/Sep/2013

Title: Hemostatic Effects of Glucono-Delta-Lactone

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: 12/851041   Filing Date: 05/Aug/2010

Abstract:

Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states.

Priority: US2009-273589P Applic. Date: 2009-08-05

Inventor: SPILLERT CHARLES R [US]; PERSAUD DEBBIE [US]


Patent No.: US8532730B2  Issued: 10/Sep/2013

Title: Analyte sensor

Applicant/Assignee: DEXCOM, INC

Application No.: 11/543404   Filing Date: 04/Oct/2006

Abstract:

Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into a host's peripheral vein or artery.

Priority: US2006-543396 Applic. Date: 2006-10-04; US2006-543490 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SIMPSON PETER [US]


Patent No.: US8535662B2  Issued: 17/Sep/2013

Title: APYRASE THERAPY FOR BLEEDING CONDITIONS

Applicant/Assignee: APT THERAPEUTICS, INC

Application No.: 13/522310   Filing Date: 13/Jan/2011

Abstract:

This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are pathophysiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.

Priority: US2010-294725P Applic. Date: 2010-01-13; WO2011US21170 Applic. Date: 2011-01-13

Inventor: CHEN RIDONG [US]; JEONG SOON SEOG [US]


Patent No.: US8540946B2  Issued: 24/Sep/2013

Title: PORTABLE SAMPLE ANALYZER CARTRIDGE

Applicant/Assignee: HONEYWELL INTERNATIONAL INC

Application No.: 13/220449   Filing Date: 29/Aug/2011

Abstract:

A sample analyzer cartridge for use at a point of care of a patient such as in a doctor's office, in the home, or elsewhere in the field. By providing a removable and/or disposable cartridge with all of the needed reagents and/or fluids, the sample analyzer can be reliably used outside of the laboratory environment, with little or no specialized training.

Priority: US2005-908460 Applic. Date: 2005-05-12; US2004-571235P Applic. Date: 2004-05-14

Inventor: PADMANABHAN ARAVIND [US]; COX JAMES A [US]; CABUZ CLEOPATRA [US]


Patent No.: US8541565B2  Issued: 24/Sep/2013

Title: Polynucleotide encoding anti-CD14 antibody fusion protein

Applicant/Assignee: MOCHIDA PHARMACEUTICAL CO., LTD

Application No.: 13/547548   Filing Date: 12/Jul/2012

Abstract:

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Priority: JP20050164901 Applic. Date: 2005-06-03; US2007-791888 Applic. Date: 2007-05-30; WO2006JP311255 Applic. Date: 2006-06-05

Inventor: FURUSAKO SHOJI [JP]; NAKAYAMA KAZUYUKI [JP]; HOSAKA YOSHITAKA [JP]; KAWAHARA TETSUSHI [JP]; NAKAMURA MASAKI [JP]; TAKEUCHI TAKASHI [JP]


Patent No.: US8545831B2  Issued: 01/Oct/2013

Title: Compositions and methods for treating a damaged cardiovascular element

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 11/443594   Filing Date: 31/May/2006

Abstract:

In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset.

Priority: US2005-685831P Applic. Date: 2005-05-31

Inventor: ROY JOSEE [US]; AYALA HEZI-YAMIT [US]; SULLIVAN CAROL [US]; CHEN MINGFEI [US]


Patent No.: US8546096B2  Issued: 01/Oct/2013

Title: Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 13/002501   Filing Date: 21/Aug/2009

Abstract:

A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence of FXI, the method comprising: a) combining a blood or plasma sample having activation competent FXI with a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample

b) combining a corresponding blood or plasma sample deficient In activation competent FXI with a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other.

Priority: US2008-189734P Applic. Date: 2008-08-22; WO2009EP06082 Applic. Date: 2009-08-21

Inventor: DOCKAL MICHAEL [AT]; SCHEIFLINGER FRIEDRICH [AT]; TURECEK PETER [AT]


Patent No.: US8548772B2  Issued: 01/Oct/2013

Title: AUTOMATED METHOD AND APPARATUS FOR DETECTING ERRONEOUS SAMPLE COLLECTION IN CLINICAL ASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 13/565930   Filing Date: 03/Aug/2012

Abstract:

An automatic method for identifying biological samples that are collected using the wrong blood preservative for subsequent analytical testing. The method also provides for identification and/or suppression of certain analytical test results that are substantially or partly adversely affected. The invention is particularly suited for use in point-of-care medical diagnostic testing.

Priority: US2008-339886 Applic. Date: 2008-12-19; US2007-015582P Applic. Date: 2007-12-20

Inventor: BROUWER ERIC [CA]; TIRINATO JODY ANN [US]; ZELIN MICHAEL P [US]


Patent No.: US8551152B2  Issued: 08/Oct/2013

Title: DRUG-ELUTING STENT AND DELIVERY SYSTEM WITH TAPERED STENT IN SHOULDER REGION

Applicant/Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC

Application No.: 13/727327   Filing Date: 26/Dec/2012

Abstract:

A drug-eluting stent delivery system for the treatment of edge restenosis in a blood vessel. The drug-eluting stent delivery system has a balloon disposed about at least a portion of a catheter, the balloon having a first end and a second end and a working length therebetween, the first end and the second end each including a tapered portion, each tapered portion being attached to the catheter, the balloon being inflatable from a collapsed configuration to an inflated configuration. A drug-eluting stent contacts a wall of the blood vessel to maintain the patency of the vessel. The drug-eluting stent has a first end and a second end, the first end and the second end each including a tapered portion, wherein the drug-eluting stent is disposed over the balloon such that at least a portion of the first end and the second end of the balloon are covered by the tapered drug-eluting stent.

A method for making the same is also disclosed herein.

Priority: US201113285627 Applic. Date: 2011-10-31; US2006-646781 Applic. Date: 2006-12-28; US2003-353219 Applic. Date: 2003-01-27

Inventor: PACETTI STEPHEN DIRK [US]


Patent No.: US8551155B2  Issued: 08/Oct/2013

Title: Stent customization system and method

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE, THE INVENTION SCIENCE FUND I, LLC

Application No.: 11/455010   Filing Date: 16/Jun/2006

Abstract:

Methods and systems are described for receiving a parameter relating to a specific patient, and for customizing one or more attributes of a stent ex situ as an at-least-roughly contemporaneous response to receiving the parameter relating to the specific patient or for customizing one or more junctions of a stent ex situ in response to the received parameter relating to the specific patient.

Priority:

Inventor: JUNG EDWARD K Y [US]; LANGER ROBERT [US]; LEUTHARDT ERIC C [US]; LEVIEN ROYCE A [US]; LORD ROBERT W [US]; MALAMUD MARK A [US]; RINALDO JR JOHN D [US]; TEGREENE CLARENCE T [US]; WOOD JR LOWELL L [US]


Patent No.: US8551555B2  Issued: 08/Oct/2013

Title: BIOCOMPATIBLE COATINGS FOR MEDICAL DEVICES

Applicant/Assignee: INTEL CORPORATION

Application No.: 11/964428   Filing Date: 26/Dec/2007

Abstract:

Biocompatible coatings for implantable medical devices are disclosed. Embodiments of the invention provide methods for coating an object with a biocompatible coating wherein the device is suspended using a flowing gas during the coating process. Embodiments of the invention provide tropoelastin coatings and methods of creating tropoelastin coatings for implantable medical devices. Optionally, the biocompatible coating can be a drug eluting coating.

Priority:

Inventor: BURGHARD JOHN [US]; CAMPBELL CARMEN [US]; YOUNKIN TODD R [US]; KUHN MARKUS [US]; SHYKIND DAVID [US]; MAIZ JOSE [US]


Patent No.: US8557535B2  Issued: 15/Oct/2013

Title: Methods for preparation of platelet rich plasma

Applicant/Assignee: INCEPT LLC

Application No.: 12/555970   Filing Date: 09/Sep/2009

Abstract:

A method of preparing a fibrinogen rich composition is disclosed. One embodiment of the method involves contacting plasma with a hydrogel capable of increasing in mass upon contact with said plasma

maintaining said contact for a period of time sufficient for said hydrogel to absorb a substantial amount of at least the water from said plasma to produce a swollen hydrogel and a fibrinogen rich phase

and separating said fibrinogen rich phase from said swollen hydrogel

whereby said fibrinogen rich composition is produced.

Priority: US2007-725751 Applic. Date: 2007-03-20; US2002-293453 Applic. Date: 2002-11-13; US2002-068807 Applic. Date: 2002-02-05; US1999-147897 Applic. Date: 1999-08-30; WO1997US16897 Applic. Date: 1997-09-22; US1996-026526P Applic. Date: 1996-09-23; US1997-039904P Applic. Date: 1997-03-04; US1997-040417P Applic. Date: 1997-03-13

Inventor: PATHAK CHANDRASHEKHAR P [US]


Patent No.: US8557762B2  Issued: 15/Oct/2013

Title: Snake Factor V and Methods of Use Thereof as a Procoagulant

Applicant/Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Application No.: 13/130378   Filing Date: 23/Nov/2009

Abstract:

Compositions and Methods for the treatment of coagulation disorders using Factor V variants are provided. Preferred disorders include hemophilia A and B.

Priority: US2008-116913P Applic. Date: 2008-11-21; WO2009US65515 Applic. Date: 2009-11-23

Inventor: CAMIRE RODNEY [US]; BOS METTINE H A [NL]


Patent No.: US8559007B2  Issued: 15/Oct/2013

Title: SYSTEMS FOR MEASURING PROPERTIES OF A PHYSIOLOGICAL FLUID SUSPENSION

Applicant/Assignee: AGGREDYNE, INC

Application No.: 13/547729   Filing Date: 12/Jul/2012

Abstract:

A method of evaluating a property of a physiological fluid suspension comprises measuring a value of the property of a liquid portion of the physiological fluid suspension via light scattering, and comparing the measured value with a reference value to evaluate the property of the liquid portion of the physiological fluid suspension.

Priority: US2009-398480 Applic. Date: 2009-03-05; US2008-068354P Applic. Date: 2008-03-05

Inventor: SUKAVANESHVAR SIVAPRASAD [US]; TEITEL EDWARD R [US]; MOHAMMAD SYED F [US]


Patent No.: US8563258B2  Issued: 22/Oct/2013

Title: ALLERGY TEST BASED ON FLOW CYTOMETRIC ANALYSIS

Applicant/Assignee: BUHLMANN LABORATORIES AG

Application No.: 12/677402   Filing Date: 11/Sep/2008

Abstract:

The invention pertains to a method for the determination of basophil activation induced by a test substance by flow cytometric measurement of the changes of the mean or median fluorescence intensities (MFI) of the basophilic FcepsilonRI receptor present on the cell surface of basophils (MFI-FcepsilonRI) and/or the IgE antibodies bound to the FcepsilonRI receptor (MFI-IgE), and the CD63 antigen exposed on the cell surface of basophils after their activation (MFI-CD63), by means of a mixture of anti-CD63, anti-FcepsilonRI or anti-IgE, and anti-CCR3 antibodies each labelled with a distinct fluorophore, of which at least one antibody acts as a basophil selection marker and at least two antibodies act as basophil activation markers, and bringing the mean fluorescence intensities of the activation markers in correlation to obtain an Activation Index.

These methods combining the measurement of an early (such as IgE, FcepsilonRI or CD203c) and a late basophil activation marker (such as CD63), respectively, provide a markedly improved clinical sensitivity in allergy diagnosis over existing methods which consider only one activation marker, such as CD203c or CD63, expressed in percentage of basophil activation. It is also an aspect of the present invention to provide an ex-vivo allergy provocation test comprising the above-mentioned flow cytometric measurement and analysis of the results as well as a test kit for carrying out the test in-vitro.

Priority: EP20070017775 Applic. Date: 2007-09-11; WO2008EP07494 Applic. Date: 2008-09-11

Inventor: SAINTE-LAUDY JEAN [FR]; SCHNEIDER MICHAEL [CH]; WEBER JAKOB MATTHIAS [CH]


Patent No.: US8563690B2  Issued: 22/Oct/2013

Title: Modulation of Platelet Aggregation

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Application No.: 12/611446   Filing Date: 03/Nov/2009

Abstract:

Methods and compositions for inhibition of platelet cell aggregation are described. In particular, compositions comprising cell permeant RGT peptides, such as RGT bound to a lipid moiety are provided. Compositions may be used in the treatment and prevention of clot related diseases such as stroke and myocardial infarction.

Priority: US2008-110740P Applic. Date: 2008-11-03

Inventor: DU XIAOPING [US]; XI XIAODONG [CN]


Patent No.: US8568448B2  Issued: 29/Oct/2013

Title: CLOTTING CASCADE INITIATING APPARATUS AND METHODS OF USE AND METHODS OF CLOSING WOUNDS

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 13/724520   Filing Date: 21/Dec/2012

Abstract:

Wound closure methods and apparatuses are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site. Methods and apparatuses for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US2006-337278 Applic. Date: 2006-01-23; US2002-291278 Applic. Date: 2002-11-08; US2000-732423 Applic. Date: 2000-12-07; US1998-212080 Applic. Date: 1998-12-15; US1997-069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]


Patent No.: US8569010B2  Issued: 29/Oct/2013

Title: MASS SPECTROMETRIC DIAGNOSIS OF SEPTICEMIA

Applicant/Assignee: BRUKER DALTONIK GMBH

Application No.: 13/322363   Filing Date: 14/Jul/2010

Abstract:

The invention mainly relates to the mass spectrometric identification of pathogens in blood cultures from blood-stream infections (septicemia). The invention provides a method with which microbial pathogens can be separated in purified form from blood after a relatively brief cultivation in a blood culture flask, without any interfering human proteins or any residual fractions of blood particles such as erythrocytes and leukocytes, and can be directly identified by mass spectrometric measurement of their protein profiles. The method is based on the use of relatively strong tensides to destroy the blood particles by dissolving the weak cell membranes and most of the internal structures of the blood particles

in spite of the fact that tensides are regarded as strong ionization inhibitors in MALDI and other ionization processes required for mass spectrometric measurements.

This method allows unknown pathogens to be obtained in their pure form by centrifuging or filtration and to be identified on the taxonomic level of species or subspecies. Problems with DNA from high levels of leukocytes can be resolved by special measures. After sufficient cultivation, the identification in a mass spectrometric laboratory takes only half an hour.

Priority: DE20091033368 Applic. Date: 2009-07-16; WO2010EP60098 Applic. Date: 2010-07-14

Inventor: MAIER THOMAS [DE]


Patent No.: US8575129B2  Issued: 05/Nov/2013

Title: AMIDES OF HYALURONIC ACID AND THE DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION

Applicant/Assignee: FIDIA FARMACEUTICI S.P.A

Application No.: 12/623253   Filing Date: 20/Nov/2009

Abstract:

An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (I): wherein R=NR6R7, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid

R1, R2, R3, R4=H, SO3-, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH2)2-COOY

Y=negative charge, or H

R5=-CO-CH3, H, SO3-, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acylic group of hyaluronic acid

R6=is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted

R7=is H or an aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted

wherein at least one of R or R5 forms an amide group.

Priority: IT1998PD00169 Applic. Date: 1998-07-06; US2002-220853 Applic. Date: 2002-09-06; WO1999IB01254 Applic. Date: 1999-07-06

Inventor: BELLINI DAVIDE [IT]; TOPAI ALESSANDRA [IT]


Patent No.: US8586006B2  Issued: 19/Nov/2013

Title: ORGAN-SPECIFIC PROTEINS AND METHODS OF THEIR USE

Applicant/Assignee: HOMESTEAD CLINICAL CORPORATION, INSTITUTE FOR SYSTEMS BIOLOGY, INTEGRATED DIAGNOSTICS, INC

Application No.: 12/376951   Filing Date: 09/Aug/2007

Abstract:

The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins/transcripts in blood, biological tissue or other biological fluid.

Priority: US2006-836986P Applic. Date: 2006-08-09; WO2007US17868 Applic. Date: 2007-08-09

Inventor: HOOD LEROY [US]; BECKMANN PATRICIA M [US]; JOHNSON RICHARD [US]; MARELLI MARCELLO [US]; LI XIAOJUN [US]


Patent No.: US8591450B2  Issued: 26/Nov/2013

Title: DIALYSIS CATHETER

Applicant/Assignee: REX MEDICAL L.P

Application No.: 13/108154   Filing Date: 16/May/2011

Abstract:

A dialysis catheter including a first portion having an outer wall having a first diameter, an elongated distal portion having a second diameter smaller than the first diameter, and a transition region between the first portion and distal portion. A first longitudinally extending venous lumen is configured to deliver blood. First and second independent longitudinally extending arterial lumens are configured to withdraw blood from a patient. The venous lumen and arterial lumen have first and second regions each positioned a first distance from the outer wall of the catheter and a third region positioned a second shorter distance from the outer wall of the catheter to form an arch shaped wall portion progressively increasing in thickness from the third region toward the first region and from the third region to the second region.

Priority: US2010-352195P Applic. Date: 2010-06-07

Inventor: DEFONZO STEPHAN A [US]


Patent No.: US8591572B2  Issued: 26/Nov/2013

Title: Surgical implant, method for the production and use thereof

Applicant/Assignee: AESCULAP AG & CO. KG, AESCULAP AG

Application No.: 12/385045   Filing Date: 30/Mar/2009

Abstract:

A surgical implant is made from biocompatible fiber material as a woven textile fabric, in particular in the form of a vascular prosthesis, the woven fabric being so configured that its permeability to blood is so low that the blood impregnates the textile fabric upon implantation and seals it off by coagulating, but does not flow through it.

Priority: DE2001125712 Applic. Date: 2001-05-21; US2004-478128 Applic. Date: 2004-04-30; WO2002EP05544 Applic. Date: 2002-05-21

Inventor: BENTELE FRANZ [DE]; GOLDMANN HELMUT [DE]


Patent No.: US8600470B2  Issued: 03/Dec/2013

Title: Method for detecting an analyte in blood

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 13/233338   Filing Date: 15/Sep/2011

Abstract:

The methods and apparatus for detecting an analyte in blood are useful for detecting an analyte in tissue of a subject. The apparatus comprises a sensor, which comprises an elongated conductive material having a protrudent end, the protrudent end comprising an electrode that detects the presence of an analyte

a substrate affixed to the conductive material

and a support having an external surface, a proximal end, and a distal end. The conductive material is positioned on the support and the protrudent end of the conductive material protrudes beyond the distal end of the support. Optionally, the sensor is suspended within the lumen of a venous flow device. Typically, only a portion of the sensor is suspended within the lumen of the venous flow device, said portion comprising the protrudent end of the conductive material.

Alternatively, the conductive material is positioned on the external surface of the intravenous infusion catheter.

Priority: US2006-348894 Applic. Date: 2006-02-07; US2004-935954 Applic. Date: 2004-09-08

Inventor: VAN ANTWERP NANNETTE M [US]; HOSS UDO [US]


Patent No.: US8603064B2  Issued: 10/Dec/2013

Title: DOUBLE BALLOON CATHETER AND METHODS FOR HOMOGENEOUS DRUG DELIVERY USING THE SAME

Applicant/Assignee: TYCO HEALTHCARE GROUP LP, COVIDIEN LP

Application No.: 13/446400   Filing Date: 13/Apr/2012

Abstract:

The present disclosure is directed to a catheter for site-specific delivery of a therapeutic agent to a blood vessel of a patient. The catheter further includes an elongated shaft having at least one inner lumen, a distal end and a proximal end and proximal and distal vessel-conforming balloons where each is separately positionable and inflatable, and when inflated, substantially restricts blood flow in the vessel and creates a treatment window of a defined but variable length for delivery of the therapeutic agent. The catheter optionally includes at least one marker band adjacent to the proximal balloon and at least one marker band adjacent to the distal balloon.

At least one lateral aperture positioned in the window is in fluid communication with a drug delivery conduit located within either the inner shaft or the outer shaft to provide a homogeneous concentration of the therapeutic agent to the window.

Priority: US2009-564771 Applic. Date: 2009-09-22; US2008-099127P Applic. Date: 2008-09-22

Inventor: HATTANGADI NEIL [US]; LERNER DANIEL [US]; OLIVERA RYAN [US]


Patent No.: US8603821B2  Issued: 10/Dec/2013

Title: METHOD FOR PREPARING SERUM AND SERUM PREPARATION APPARATUS

Applicant/Assignee: JMS CO., LTD

Application No.: 12/529664   Filing Date: 05/Mar/2008

Abstract:

A method for preparing serum and a serum preparation apparatus is provided that can give a large amount of serum with high culture efficiency regardless of freshness of blood used. In a method for preparing serum from blood containing at least platelets, a platelet processing step is provided in which platelet membrane in the blood is destroyed. After the platelet processing step, a deposition step for depositing thermolabile protein in blood and a removal step for removing the thermolabile protein, which has been deposited in the deposition step, are preferably provided.

Priority: JP20070057071 Applic. Date: 2007-03-07; WO2008JP53972 Applic. Date: 2008-03-05

Inventor: SUZUKI KOJI [JP]; TANAKA SEISHIN [JP]; HIRAI SATOSHI [JP]; TAKABATAKE MARI [JP]


Patent No.: US8608953B2  Issued: 17/Dec/2013

Title: Metabolic Detoxification System and Method

Applicant/Assignee: VITAL THERAPIES, INC

Application No.: 13/361812   Filing Date: 30/Jan/2012

Abstract:

An extracorporeal filtration and detoxification system and method generally comprise separating ultrafiltrate from cellular components of blood, treating the ultrafiltrate independently of the cellular components in a recirculation circuit, recombining treated ultrafiltrate and the cellular components, and returning whole blood to the patient. A recirculation circuit generally comprises an active cartridge including active cells operative to effectuate a selected treatment

in some embodiments, the active cells are the C3A cell line.

Priority: US2005-064566 Applic. Date: 2005-02-23; US2004-565888P Applic. Date: 2004-04-27

Inventor: BROTHERTON JOHN D [US]; HE DAR [US]


Patent No.: US8618057B2  Issued: 31/Dec/2013

Title: ANTICOAGULANT AND COMPOSITION FOR PREVENTING THROMBUS CONTAINING POLY-GAMMA-GLUTAMIC ACID

Applicant/Assignee: BIOLEADERS CORPORATION

Application No.: 13/444324   Filing Date: 11/Apr/2012

Abstract:

The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood vessels, shows an excellent sustained-release effect and is harmless to the human body. Thus, it is useful as a high-value-added anticoagulant and a food or beverage composition for preventing thrombus formation.

Priority: KR20050133055 Applic. Date: 2005-12-29; US2008-159561 Applic. Date: 2008-10-30; WO2006KR05685 Applic. Date: 2006-12-22

Inventor: SUNG MOON-HEE [KR]; PARK CHUNG [KR]; HONG SEUNG-PYO [KR]; POO HARYOUNG [KR]; KIM TAE-WOO [KR]